|
|
|
|
deaths (OS) | progression or deaths (PFS) | RFS/DFS |
laHNSCC - 1st line (L1) locally advanced (laHNSCC) laHNSCC - 1st line (L1) |
mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population |
|
| pembrolizumab alone vs. cetuximab plus platin plus 5FU | 1 | 0.83 [0.70; 0.99], 1 RCT, I2=0% unassessable degree of certainty | 1.34 [1.13; 1.59], 1 RCT, I2=0% statistically significant harm | - |
| pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU | 1 | 0.77 [0.63; 0.94], 1 RCT, I2=0% conclusive unassessable degree of certainty | 0.92 [0.77; 1.10], 1 RCT, I2=0% inconclusive result | - |
mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive |
|
| pembrolizumab alone vs. cetuximab plus platin plus 5FU | 2 | 0.78 [0.64; 0.96], 1 RCT, I2=0% conclusive unassessable degree of certainty | 1.16 [0.96; 1.40], 1 RCT, I2=0% inconclusive result | - |
| pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU | 2 | 0.63 [0.51; 0.77], 1 RCT, I2=0% conclusive unassessable degree of certainty | 0.82 [0.67; 1.00], 1 RCT, I2=0% inconclusive result | - |
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population |
|
| pembrolizumab alone vs. Standard of Care (SoC) | 1 | 0.80 [0.65; 0.98], 1 RCT, I2=0% conclusive unassessable degree of certainty | 0.96 [0.79; 1.16], 1 RCT, I2=0% inconclusive result | - |
mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative |
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive |
|
| pembrolizumab alone vs. Standard of Care (SoC) | 1 | 0.74 [0.58; 0.94], 1 RCT, I2=0% conclusive unassessable degree of certainty | 1.01 [0.81; 1.26], 1 RCT, I2=0% inconclusive result | - |